Veradermics, Incorporated MANE R3KPHARMA
Company Overview
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Why Investors Should Care
Generates a return on equity of 57.8%, reflecting efficient use of shareholder capital.
Carries low leverage with a debt-to-equity ratio of 0.05.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +175.05% |
| 6 Months: | +102.32% |
| 3 Months: | +14.96% |
| 1 Month: | -9.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)49.77 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 57.8%.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MANE Veradermics, Incorporated R3KPHARMA | 103.83 | -41.53 | $4.34B | 0.00% | -50.43% | 57.84% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Operating Income | -12.91M | -29.86M |
| Net Income | -12.40M | -27.23M |
| Diluted EPS | -19.79 | -1.32 |
| R&D Expense | 11.45M | 20.93M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Income | -26.78M | -72.35M |
| Net Income | -26.49M | -70.00M |
| Diluted EPS | -37.05 | -111.91 |
| R&D Expense | 23.28M | 62.06M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 55.53M | 152.62M |
| Total Equity | -22.24M | -48.48M | -121.01M |
| Cash & Equivalents | - | 53.08M | 21.77M |
| Total Liabilities | - | 4.72M | 9.16M |
| Current Liabilities | - | 4.72M | 9.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -23.69M | -71.60M |
| Investing Cash Flow | 0 | -118.86M |
| Financing Cash Flow | 60.48M | 159.14M |
| Capital Expenditure | -0 | -24.00K |
| Free Cash Flow | -23.69M | -71.63M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 54.6% | 57.8% |
| ROCE % | -52.7% | -50.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Montanova Capital LLC | 9.98% | 4.17M | $445.04M |
| 2 | FMR, LLC | 7.67% | 3.20M | $342.13M |
| 3 | SR One Capital Management, LP | 5.75% | 2.40M | $256.40M |
| 4 | Deep Track Capital, Lp | 4.79% | 2.00M | $213.50M |
| 5 | Citadel Advisors Llc | 4.49% | 1.88M | $200.45M |
| 6 | Siren, L.L.C. | 3.96% | 1.66M | $176.71M |
| 7 | Blackrock Inc. | 3.81% | 1.59M | $170.14M |
| 8 | Viking Global Investors, L.P. | 3.74% | 1.56M | $166.69M |
| 9 | JPMORGAN CHASE & CO | 2.79% | 1.17M | $124.43M |
| 10 | Aberdeen Group plc | 2.62% | 1.10M | $117.07M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MANE
Top Veradermics (MANE) Competitors 2026 - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE9PX0RJOVQ3c3FPXzZyRzdjU09OVnNZemtKbk8tMDlSMl8zaGpJanA1MEdNUHpwRnFOTm1DMnZEa0pMdnpCdGJ2VDNuOGJZRk9yMGJVSnFBc0hPakJqQTBzX09JY3V6V2pUOFd6V2JsZ1ZZQk5ldkpFMTVnV2JYUQ?oc=5" target="_blan…
Veradermics (MANE) Stock Looks Overvalued After Its 161% Rally - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPb0VqNzFhUWhTLTBTSlN5Zkx0M0llZ09EYWlKNlBjejBxY1pqQ21SemVDWUd3dDBUMlBKY3VQdlh1Mm0zdEdiU2R0dng5SnI0ZEhRZS1OVEZyNENiTU9RbWxROVNNaFpmLUZoRHB1WUlfX091OS01dUJ0a09BR0hFbFctX3FVZTlOU2ZiWl…
Veradermics (MANE) R&D chief receives new stock and option awards - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOcVVILVUwX19VU0VYRlJTLXVJN2ppMzFqR1lmcWFFNFB4SkpEdWlFOHhZbXFGMm1wdElwdWczcjN1alNNeXVmRWZzYUpUUE43N3cyWXY1TEZjZEY2cHNVM2JiWnQ4dnBWTmhVdzdWRlRfem55T1BTR056Q2RXbzJCTFhyUlp5UEdtVU1HOU…
Insider Sale: Director at $MANE Sells 690,601 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNMi16d2NKYXZnbDFBX2d4Xy1HNkhEeHNTaFFER0U3Qk9YTmxxSEdOalJtS241a29UcEFGVDhFaVUya1huUXk3U1pZR3g1eFJZYnJ5Q0hxTVc3dzVVXzRCN3lOZEJLR05sRU9BWXYtU1dQWHpXVksyRHFGTHN3Ti1MMkVMVFJWZ3BoMXYyeX…
Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine - Fortune
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPU2tFR01HUWx1eks2bWNfdGFjXzFPb0p3a1dWeElBdnhXcFRFM3NBUDFHakRudW00cmZlZ2kzY1pZZzBmU1NUbTdkQ09YNDNDLXpZbnYycVBCRnFEOXp4bEUyWS03blIzb1A2VElPazI3Z1c2QkNvWWtCendUUjk1cTVQcmRucWlTUnpjd1…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBPWHFRazByeWpNaG8zZ0VzTUhsd1owanNxOFBaWHhlOGYtMjd2QXVRbWFmbkptQl9vdnRILUc5N0tvQ0pqY1ZQdkVUQUxHay1f?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
MANE — Frequently Asked Questions
What is the current share price of Veradermics, Incorporated (MANE)?
As of 2026-09-19 21:16 PDT, Veradermics, Incorporated (MANE) trades at $103.83 on NYSE. Its 52-week range is $37.03 to $129.74.
What is the market capitalisation of MANE?
Veradermics, Incorporated (MANE) has a market capitalisation of $4.34B on NYSE.
What is the P/E ratio of MANE?
MANE trades at a trailing price-to-earnings (P/E) ratio of -41.53. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.48.
What is the return on equity (ROE) of MANE?
MANE has a return on equity (ROE) of 57.84%. Its return on capital employed (ROCE) is -50.43%.
Is MANE a good stock to buy?
This page provides a data-driven analysis of Veradermics, Incorporated (MANE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.